Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia-Reference-Cited by-同舟云学术

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

Published:2019-04-05 Issue:6 Volume:21 Page:1474-1482
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ji Linong¹^ORCID,Liu Yanmei²,Miao Heng³,Xie Yongli⁴,Yang Ming⁵,Wang Wei⁵,Mu Yuting⁵,Yan Ping⁵,Pan Sharon⁶,Lauring Brett⁷,Liu Shu⁸,Huyck Susan⁷,Qiu Yanping⁸,Terra Steven G.⁹^ORCID

Affiliation:

1. Peking University People's Hospital Beijing China

2. Yancheng First People's Hospital Yancheng China

3. The Second Affiliated Hospital of Nanjing Medical University Nanjing China

4. Pingxiang People's Hospital Pingxiang China

5. Pfizer (China) R&D Co. Shanghai China

6. Pfizer Inc. New York New York

7. Merck & Co., Inc. Kenilworth New Jersey

8. MSD China Beijing China

9. Pfizer Inc. Andover Massachusetts

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13681

Reference27 articles.

1. Prevalence and Control of Diabetes in Chinese Adults

2. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: A systematic review

3. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

4. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibitor-induced ketoacidosis – A diagnostic challenge;Medicover Journal of Medicine;2024-04

2. Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2023-11-17

3. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

4. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-06-13

5. Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis;Medicine;2023-03-10